Researchers review the future of schizophrenia treatment, highlighting TAAR1 agonists, NMDA enhancers, and the gut-brain axis ...

The FDA OKs pill schizophrenia and bipolar disorder treatment with Bysanti, a new atypical antipsychotic approved for adults.

Milsaperidone is an active metabolite of iloperidone ...

Antipsychotic medicines are a key part of the pharmacological treatment of schizophrenia. Although they provide therapeutic ...

Milsaperidone, a new chemical entity, is the major active metabolite of iloperidone (Fanapt) and had been demonstrated to be bioequivalent to iloperidone.

By Sneha S K and Kunal Das Feb 20 (Reuters) - The U.S. Food and Drug Administration has approved Vanda Pharmaceuticals' drug ...

Daybue was turned down for Rett syndrome, and Iloperidone for schizophrenia and bipolar I, with safety and benefit-risk concerns cited in both cases.

In February 2026, Sanofi and Teva Pharmaceutical Industries reported positive long-term phase 2b extension results for ...

Bysanti is based on iloperidone, an active metabolite of a compound that forms the core of Fanapt, another drug by Vanda Pharmaceuticals.

Scientists have found a new way to study serious mental health conditions by growing very small human brains in the lab. These tiny brains are about the size of a pea, but they may help doctors better ...